Cardiology Letters 2020, 29(2):97-101
Polypill in seniors: possible frequency of fixed drug combination according to the SAFIS study
- 1 Klinika geriatrie LFUK a UN Bratislava
- 2 Oddelenie vnútorného lekárstva a geriatrie, FNsP J. A. Reimana v Prešove
- 3 Oddelenie geriatrie a dlhodobo chorých, FN Trenčín
- Oddelenie dlhodobo chorých NsP Prievidza - Nemocnica Bojnice, Slovenská republika
Aims: Polypharmacy is one of the most typical features of geriatrics. Unreliable drug usage belongs to its risks, among others. One way of reducing this risk is to integrate more drugs into one tablet (polypill). Nowadays this could be done especially in cardiovascular medicine. Real world data from the health care provided in Slovakia, which would reflect the potential for switching from more tabs with one drug towards the polypill in seniors, are almost unknown.
Methods: We used the "Slovak Audit of atrial FIbrillation Study" (SAFIS) data (3 706 patients, average age 80.5 years) and evaluated how frequently patients had the combination of an angiotensin converting enzyme inhibitor (ACEI) or an AT1-receptor for angiotensin II inhibitor (ARB) and a diuretic, an ACEI/ARB and a betablocker (BB), an ACEI/ARB and a statin or at least 3 out of these 4 drug groups at discharge.
Results: The average number of recommended drugs was 9.1 at discharge. A diuretic, BB, statin or ACEI/ ARB was recommended in 68.9, 64.1, 31.9 and 52.4% of patients respectively. Simultaneous treatment with a diuretic and an ACEI/ARB, BB and an ACEI/ARB, statin and an ACEI/ARB was recommended in 37.9, 36.2, and 19.7% patients respectively. The frequency of these co-treatments was typically higher than 40% in 65-79 yrs. old, declining with age moderately, but staying above 20% even in the oldest (90 yrs. and older) for combinations of an ACEI/ARB with a diuretic or a BB. At least 3 drugs from the groups ACEI/ARB, BB, diuretics, statins were recommended in 38.6% of patients.
Conclusion: The potential for the reduction of the number of daily used tablets with their integration in a polypill is really high in seniors.
Keywords: fixed drug combination; polypill; geriatrics; diuretics; angiotensin converting enzyme inhibitors; sartans; beta-blockers; statins
Published: February 1, 2020 Show citation
References
- Mangoni A, Jansen P, Jackson S. Clinical pharmacology of ageing. In: Jackson S, Jansen P, Mangoni A (Eds.). Prescribing for elderly patients. Chichester: Wiley-Blackwell; 2009:1-12.
Go to original source... - Burkhardt H. Polypharmacy. In: Wehling E (Ed.). Drug therapy for the elderly. Wien: Springer-Verlag; 2013:319-329.
Go to original source... - Slattum PW, Ogbonna KC, Peron EP. The pharmacology of aging. In: Fillit HM, Rockwood K, Young J (Eds.). Brocklehurst´s textbook of geriatric medicine and gerontology. Philadelphia: Elsevier; 2017:160-165.
- Dúbrava M. Realita polymorbidity. Geriatria 2008;14:55-57.
- Hegyi L. Zvláštnosti terapie vo vyššom veku. In: Hegyi L, Krajčík Š (Eds.). Geriatria. Bratislava: Herba; 2010:98-105.
- Gill SS, Seitz DP. Simplifying the pillbox: drugs and ageing. In: Holroyd-Leduc J, Reddy M (Eds.). Evidence-based geriatric medicine. Chichester: Wiley-Blackwell; 2012:25-42.
Go to original source... - Burkhardt H. Adherence to pharmacotherapy in the elderly. In: Wehling E (Ed.). Drug therapy for the elderly. Wien: SpringerVerlag; 2013:313-318.
Go to original source... - Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
Go to original source... - Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104.
Go to original source... - Tykarski A, Widecka K, Narkiewicz K, et al. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiol Pol 2017;75:13571367.
Go to original source... - Wiley B, Fuster V. The concept of the polypill in the prevention of cardiovascular disease. Ann Glob Health 2014;80:24-34.
Go to original source... - Dúbrava M, Németh F, Drobná T, et al. Fibrilácia predsiení u seniorov: základné dáta zo štúdie SAFIS (metodika, prevalencia a typy fibrilácie predsiení). Geriatria 2016; 21:8-19.
- Nguyen TN, Cumming RG, Hilmer SN. The impact of frailty on mortality, length of stay and re-hospitalisation in older patients with atrial fibrillation. Heart Lung Circ 2016;25:551557.
Go to original source... - Kim SW, Yoon SJ, Choi JY, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch Gerontol Geriatr 2017;70:1-7.
Go to original source... - Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 2011;22:597-602.
Go to original source... - Fumagalli S, Nieuwlaat R, Tarantini F. Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation. Aging Clin Exp Res 2012;24:517523.
Go to original source... - Tinetti ME, McAvay G, Trentalange M, et al. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ 2015;Oct 2,351:h4984.
Go to original source... - Roy A, Naik N, Srinath Reddy K. Strengths and limitations of using the polypill in cardiovascular prevention. Curr Cardiol Rep 2017;19:45.
Go to original source... - Teo K, Yusuf S. Polypill Variants (Quarter Pill Trials). Am J Hypertens 2018;31:758-761.
Go to original source... - Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? Ther Adv Drug Saf 2018;9:157-162.
Go to original source...

